达卡巴嗪
黑色素瘤
医学
转移
癌症研究
辛伐他汀
内科学
氟伐他汀
药理学
肿瘤科
癌症
作者
Masanobu Tsubaki,Tomoya Takeda,Naoya Obata,Keishi Kawashima,Mitsuki Tabata,Motohiro Imano,Takao Satou,Shozo Nishida
摘要
Abstract Malignant melanoma is a highly aggressive skin cancer, and the overall median survival in patients with metastatic melanoma is only 6–9 months. Although molecular targeted therapies have recently been developed and have improved the overall survival, melanoma patients may show no response and acquisition of resistance to these drugs. Thus, other molecular approaches are essential for the treatment of metastatic melanoma. In the present study, we investigated the effect of cotreatment with dacarbazine and statins on tumor growth, metastasis, and survival rate in mice with metastatic melanomas. We found that cotreatment with dacarbazine and statins significantly inhibited tumor growth and metastasis via suppression of the RhoA/RhoC/LIM domain kinase/serum response factor/c‐Fos pathway and enhanced p53, p21, p27, cleaved caspase‐3, and cleaved poly(ADP‐ribose) polymerase 1 expression in vivo. Moreover, the cotreatment significantly improved the survival rate in metastasis‐bearing mice. Importantly, treatment with dacarbazine plus 100 mg/kg simvastatin or fluvastatin prevented metastasis‐associated death in 4/20 mice that received dacarbazine + simvastatin and in 8/20 mice that received dacarbazine + fluvastatin (survival rates, 20% and 40%, respectively). These results suggested that cotreatment with dacarbazine and statins may thus serve as a new therapeutic approach to control tumor growth and metastasis in melanoma patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI